6. Evidence-based medication use among Chinese patients with acute coronary

Size: px
Start display at page:

Download "6. Evidence-based medication use among Chinese patients with acute coronary"

Transcription

1 1. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale Am Heart J, (3): p e4. n&list_uids= Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) Akhter, N., et al. Am Heart J, (1): p n&list_uids= Comparative trends in guidelines adherence among patients with non-st-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative Amsterdam, E.A., et al. Am Heart J, (5): p e1. n&list_uids= Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities Ang, D.S., et al. Am Heart J, (1): p n&list_uids= Blood pressure paradox in patients with non-st-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative Bangalore, S., et al. Am Heart J, (3): p n&list_uids= Evidence-based medication use among Chinese patients with acute coronary

2 syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study Bi, Y., et al. Am Heart J, (3): p e1. n&list_uids= The paradoxical use of cardiac catheterization in patients with non-st-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative Cohen, M.G., et al. Am Heart J, (2): p n&list_uids= Acute coronary syndrome emergency treatment strategies: Improved treatment and reduced mortality in patients with acute coronary syndrome using guideline-based critical care pathways Corbelli, J.C., et al. Am Heart J, (1): p n&list_uids= Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study Drouet, L., C. Bal dit Sollier, and J. Martin Am Heart J, (2): p n&list_uids= Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada Elbarouni, B., et al. Am Heart J, (3): p n&list_uids= The expanded Global Registry of Acute Coronary Events: baseline

3 characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes Goodman, S.G., et al. Am Heart J, (2): p e1-5. n&list_uids= Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Han, Y., et al. Am Heart J, (4): p n&list_uids= Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Herman, M., et al. Am Heart J, (3): p n&list_uids= Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial James, S., et al. Am Heart J, (4): p n&list_uids= Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk Joyner, C.D., et al. Am Heart J, (3): p n&list_uids= Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events

4 Pieper, K.S., et al. Am Heart J, (6): p n&list_uids= Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy Pride, Y.B., et al. Am Heart J, (3): p. e21-6. n&list_uids= Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes Rao, R.V., et al. Am Heart J, (4): p e1. n&list_uids= Fondaparinux versus Enoxaparin in non-st-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial Sculpher, M.J., et al. Am Heart J, (5): p n&list_uids= Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes Tizon-Marcos, H., et al. Am Heart J, (4): p n&list_uids= Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-st-elevation acute coronary syndromes undergoing diagnostic angiography

5 Wang, T.Y., et al. Am Heart J, (4): p n&list_uids= Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial Wilson, S.R., et al. Am Heart J, (3): p n&list_uids= Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-st elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial Yong, G., et al. Am Heart J, (1): p. 60 e1-9. n&list_uids= Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study Zhao, S.P., et al. Am Heart J, (4): p e1. n&list_uids= Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes Abela, G.S., et al. Am J Cardiol, (7): p n&list_uids= Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-st-elevation acute coronary syndrome Allen LaPointe, N.M., et al. Am J Cardiol, (10): p

6 n&list_uids= Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin Anantharam, B., et al. Am J Cardiol, (1): p n&list_uids= Influence of age on use of cardiac catheterization and associated outcomes in patients with non-st-elevation acute coronary syndromes Bagnall, A.J., et al. Am J Cardiol, (11): p n&list_uids= Comparison of outcomes in patients > or =70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndrome Bagur, R., et al. Am J Cardiol, (5): p n&list_uids= Usefulness of age and gender in the early triage of patients with acute chest pain having cardiac computed tomographic angiography Bamberg, F., et al. Am J Cardiol, (9): p n&list_uids= Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy Cecchi, E., et al. Am J Cardiol, (6): p n&list_uids=

7 32. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients Cuisset, T., et al. Am J Cardiol, (8): p n&list_uids= Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes Depta, J.P., et al. Am J Cardiol, (9): p n&list_uids= Impact of admission glucose level and presence of diabetes mellitus on mortality in patients with non-st-segment elevation acute coronary syndrome treated conservatively Dziewierz, A., et al. Am J Cardiol, (7): p n&list_uids= Comparison of men and women with acute coronary syndrome in six Middle Eastern countries El-Menyar, A., et al. Am J Cardiol, (8): p n&list_uids= Usefulness of diabetes mellitus to predict long-term outcomes in patients with unstable angina pectoris Farkouh, M.E., et al. Am J Cardiol, (4): p n&list_uids= Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis) Gibson, C.M., et al.

8 Am J Cardiol, (1): p n&list_uids= Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE]) Goldberg, R.J., et al. Am J Cardiol, (5): p n&list_uids= Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]) Gore, J.M., et al. Am J Cardiol, (2): p n&list_uids= Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus Hasin, T., et al. Am J Cardiol, (6): p n&list_uids= Prognostic value of admission fasting glucose levels in patients with acute coronary syndrome Kolman, L., et al. Am J Cardiol, (4): p n&list_uids= Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-st-elevation acute coronary syndromes (from the ACUITY trial) Lansky, A.J., et al. Am J Cardiol, (9): p n&list_uids= Prognostic impact of types of atrial fibrillation in acute coronary syndromes

9 Lau, D.H., et al. Am J Cardiol, (10): p n&list_uids= Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome LeLeiko, R.M., et al. Am J Cardiol, (5): p n&list_uids= Comparison of site-reported and core laboratory-reported creatine kinase-mb values in non-st-segment elevation acute coronary syndrome (from the international trial SYNERGY) Linefsky, J.P., et al. Am J Cardiol, (10): p n&list_uids= Severity of coronary arterial stenoses responsible for acute coronary syndromes Manoharan, G., et al. Am J Cardiol, (9): p n&list_uids= Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome Melloni, C., et al. Am J Cardiol, (2): p n&list_uids= Anemia for risk assessment of patients with acute coronary syndromes Meneveau, N., et al. Am J Cardiol, (4): p n&list_uids= Effect of culprit-lesion remodeling versus plaque rupture on three-year outcome

10 in patients with acute coronary syndrome Okura, H., et al. Am J Cardiol, (6): p n&list_uids= Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes Olenchock, B.A., et al. Am J Cardiol, (3): p n&list_uids= Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome Porto, I., et al. Am J Cardiol, (11): p n&list_uids= Effectiveness of myocardial perfusion scintigraphy to predict coronary anatomy in patients with non-st elevation acute coronary syndrome Potter, B.J., et al. Am J Cardiol, (5): p n&list_uids= Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome Rodes-Cabau, J., et al. Am J Cardiol, (6): p n&list_uids= Arterial access-site-related outcomes of patients undergoing invasive coronary procedures for acute coronary syndromes (from the ComPaRison of Early Invasive and Conservative Treatment in Patients With Non-ST-ElevatiOn Acute Coronary Syndromes [PRESTO-ACS] Vascular Substudy) Sciahbasi, A., et al. Am J Cardiol, (6): p

11 n&list_uids= Relation of death within 90 days of non-st-elevation acute coronary syndromes to variability in electrocardiographic morphology Syed, Z., et al. Am J Cardiol, (3): p n&list_uids= Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes Tamburino, C., et al. Am J Cardiol, (2): p n&list_uids= Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) Tung, P., et al. Am J Cardiol, (8): p n&list_uids= Relation of body mass index to mortality after development of heart failure due to acute coronary syndrome Wu, A.H., et al. Am J Cardiol, (12): p n&list_uids= Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention Xinwei, J., et al. Am J Cardiol, (4): p n&list_uids=

12 60. Clinical significance of borderline elevated troponin I levels across different assays in patients with suspected acute coronary syndrome Zahid, M., et al. Am J Cardiol, (2): p n&list_uids= Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy Bonello, L., et al. Catheter Cardiovasc Interv, (7): p n&list_uids= Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes De Carlo, M., et al. Catheter Cardiovasc Interv, (3): p n&list_uids= Is computed tomography coronary angiography the most accurate and effective noninvasive imaging tool to evaluate patients with acute chest pain in the emergency department? CT coronary angiography is the most accurate and effective noninvasive imaging tool for evaluating patients presenting with chest pain to the emergency department: antagonist viewpoint Hendel, R.C. Circ Cardiovasc Imaging, (3): p ; discussion 275. n&list_uids= Is computed tomography coronary angiography the most accurate and effective noninvasive imaging tool to evaluate patients with acute chest pain in the emergency department?: CT coronary angiography is the most accurate and effective noninvasive imaging tool for evaluating patients presenting with chest pain to the emergency department Hoffmann, U. and F. Bamberg Circ Cardiovasc Imaging, (3): p ; discussion 263. n&list_uids=

13 65. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial Aoki, J., et al. Circulation, (5): p n&list_uids= Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program Brilakis, E.S., et al. Circulation, (7): p n&list_uids= Soluble CXCL16 predicts long-term mortality in acute coronary syndromes Jansson, A.M., et al. Circulation, (25): p n&list_uids= Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Marcucci, R., et al. Circulation, (2): p n&list_uids= Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial Morrow, D.A., et al. Circulation, (15): p n&list_uids= Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the

14 classification system from the universal definition of myocardial infarction Morrow, D.A., et al. Circulation, (21): p n&list_uids= Baseline risk of major bleeding in non-st-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Subherwal, S., et al. Circulation, (14): p n&list_uids= Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice Wang, T.Y., et al. Circulation, (18): p n&list_uids= Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure Abrahamsson, P., et al. Eur Heart J, (3): p n&list_uids= Improving clinical outcomes by reducing bleeding in patients with non-st-elevation acute coronary syndromes Budaj, A., et al. Eur Heart J, (6): p n&list_uids= Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-st-segment elevation acute coronary syndrome: the problem of treatment selection bias Hirsch, A., et al. Eur Heart J, (6): p

15 n&list_uids= Prognostic value of circulating chromogranin A levels in acute coronary syndromes Jansson, A.M., et al. Eur Heart J, (1): p n&list_uids= Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-st-elevation acute coronary syndromes: a risk model from the ACUITY trial Mehran, R., et al. Eur Heart J, (12): p n&list_uids= Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Michelson, A.D., et al. Eur Heart J, (14): p n&list_uids= Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells Stellos, K., et al. Eur Heart J, (5): p n&list_uids= Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-st-segment elevation acute coronary syndrome: an optical coherence tomography study Tanaka, A., et al. Eur Heart J, (11): p n&list_uids=

16 81. Temporal management patterns and outcomes of non-st elevation acute coronary syndromes in patients with kidney dysfunction Wong, J.A., et al. Eur Heart J, (5): p n&list_uids= Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes Yunoki, K., et al. Eur Heart J, (15): p n&list_uids= A comparison between B-type natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification Ang, D.S., et al. Heart, (22): p n&list_uids= Predicting freedom from clinical events in non-st-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events Brieger, D., et al. Heart, (11): p n&list_uids= Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events Dey, S., et al. Heart, (1): p n&list_uids= Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database Gale, C.P., et al. Heart, (3): p

17 n&list_uids= Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes Joynt, K.E., et al. Heart, (17): p n&list_uids= Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model Kurz, D.J., et al. Heart, (8): p n&list_uids= Secondhand smoke exposure and survival following acute coronary syndrome: prospective cohort study of 1261 consecutive admissions among never-smokers Pell, J.P., et al. Heart, (17): p n&list_uids= Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study Rahimi, K., et al. Heart, (23): p n&list_uids= Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial Redfern, J., et al. Heart, (6): p n&list_uids= Immediate versus deferred coronary angioplasty in non-st-segment elevation

18 acute coronary syndromes Riezebos, R.K., et al. Heart, (10): p n&list_uids= Pregnancy in high risk cardiac conditions Roos-Hesselink, J.W., J.J. Duvekot, and S.A. Thorne Heart, (8): p n&list_uids= Delay to angiography and outcomes following presentation with high-risk, non-st-elevation acute coronary syndromes: results from the Global Registry of Acute Coronary Events Swanson, N., et al. Heart, (3): p n&list_uids= Chest pain in the emergency department: role of cardiac imaging Wackers, F.J. Heart, (12): p n&list_uids= Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial Dangas, G., et al. J Am Coll Cardiol, (15): p n&list_uids= Prognostic value of biomarkers during and after non-st-segment elevation acute coronary syndrome Eggers, K.M., et al. J Am Coll Cardiol, (4): p n&list_uids=

19 98. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial Fraley, A.E., et al. J Am Coll Cardiol, (23): p n&list_uids= Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study) Hiro, T., et al. J Am Coll Cardiol, (4): p n&list_uids= Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial Hoffmann, U., et al. J Am Coll Cardiol, (18): p n&list_uids= Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial Jolly, S.S., et al. J Am Coll Cardiol, (5): p n&list_uids= Advanced age, antithrombotic strategy, and bleeding in non-st-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

20 Lopes, R.D., et al. J Am Coll Cardiol, (12): p n&list_uids= Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome Motoyama, S., et al. J Am Coll Cardiol, (1): p n&list_uids= Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial Nikolsky, E., et al. J Am Coll Cardiol, (14): p n&list_uids= The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis O'Donoghue, M., et al. J Am Coll Cardiol, (8): p n&list_uids= Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial Prasad, A., et al. J Am Coll Cardiol, (5): p n&list_uids= Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With

21 Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial Scirica, B.M., et al. J Am Coll Cardiol, (16): p n&list_uids= Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia Venge, P., et al. J Am Coll Cardiol, (13): p n&list_uids= Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation Waters, D.D. and I. Ku J Am Coll Cardiol, (15): p n&list_uids= Sex differences in mortality following acute coronary syndromes Berger, J.S., et al. JAMA, (8): p n&list_uids= Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome Ho, P.M., et al. JAMA, (9): p n&list_uids= Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial Montalescot, G., et al. JAMA, (9): p n&list_uids=

22 113. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Mega, J.L., et al. Lancet, (9683): p n&list_uids= Otamixaban for the treatment of patients with non-st-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Sabatine, M.S., et al. Lancet, (9692): p n&list_uids= Early versus delayed, provisional eptifibatide in acute coronary syndromes Giugliano, R.P., et al. N Engl J Med, (21): p n&list_uids= Early versus delayed invasive intervention in acute coronary syndromes Mehta, S.R., et al. N Engl J Med, (21): p n&list_uids= Ticagrelor versus clopidogrel in patients with acute coronary syndromes Wallentin, L., et al. N Engl J Med, (11): p n&list_uids= Age-related differences in virtual histology-intravascular ultrasound findings in patients with coronary artery disease Hong, Y.J., et al. J Cardiol, (2): p n&list_uids=

23 119. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction Vuilleumier, N., et al. Eur Heart J, n&list_uids= Aspects on the intensity and the relief of pain in the prehospital phase of acute coronary syndrome: experiences from a randomized clinical trial Zedigh, C., et al. Coron Artery Dis, (2): p n&list_uids= Aspirin administration in ED patients who presented with undifferentiated chest pain: age, race, and sex effects Takakuwa, K.M., F.S. Shofer, and J.E. Hollander Am J Emerg Med, (3): p n&list_uids= Assessment of ischemia-modified albumin levels for emergency room diagnosis of acute coronary syndrome Shen, X.L., et al. Int J Cardiol, n&list_uids= Characteristics and outcome of patients with acute coronary syndrome and normal or near-normal coronary angiography Minha, S., et al. Coron Artery Dis, n&list_uids= Clinical outcome after acute coronary syndrome in Japanese patients: An observational cohort study Nakamura, M., et al. J Cardiol, (1): p

24 n&list_uids= A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents Rathore, S., et al. EuroIntervention, (7): p n&list_uids= Coronary Artery Calcium Scoring in the Emergency Department: Identifying Which Patients With Chest Pain Can Be Safely Discharged Home Nabi, F., et al. Ann Emerg Med, n&list_uids= Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial Toh, S., et al. Ann Intern Med, (4): p n&list_uids= Coronary Revascularization Strategy for ST Elevation Myocardial Infarction with Multivessel Disease: Experience and Results at 1-Year Follow-Up Mohamad, T., et al. Am J Ther, n&list_uids= Coronary score adds prognostic information for patients with acute coronary syndrome Huang, G., et al. Circ J, (3): p n&list_uids= Correlation of thrombolysis in myocardial infarction (TIMI) risk score with extent of coronary artery disease in patients with acute coronary syndrome

25 Lakhani, M.S., et al. J Pak Med Assoc, (3): p n&list_uids= Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Mahoney, E.M., et al. Circulation, (1): p n&list_uids= CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients Jarvis, M.D., et al. Clin Exp Pharmacol Physiol, (2): p n&list_uids= Differences in mortality in acute coronary syndrome symptom clusters Riegel, B., et al. Am Heart J, (3): p n&list_uids= Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events Porto, I., et al. Int J Cardiol, n&list_uids= Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use Hoskins, M.H., et al. J Cardiovasc Pharmacol Ther, (1): p n&list_uids=

26 136. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Rasmussen, K., et al. Lancet, n&list_uids= Elevated CK-MB values after routine angioplasty predicts worse long-term prognosis in low-risk patients Vikenes, K., et al. Scand Cardiovasc J, (2): p n&list_uids= Eosinophil cationic protein: A new biomarker of coronary atherosclerosis Niccoli, G., et al. Atherosclerosis, n&list_uids= Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events Lopez-Sendon, J., et al. Eur Heart J, n&list_uids= Gender differences in the treatment of non-st-segment elevation myocardial infarction Tavris, D., et al. Clin Cardiol, (2): p n&list_uids= Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction Lawesson, S.S., et al. Heart, (6): p n&list_uids=

27 142. [Peculiarities of Dynamics and Prognostic Value of NT-proBNP Level in Different Variants of Treatment of Patients With Acute Coronary Syndrome.] Shreider, E.V., et al. Kardiologiia, (2): p n&list_uids= Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-st elevation acute coronary syndrome Taglieri, N., et al. Atherosclerosis, (1): p n&list_uids= Plasma levels of Hsp70 and anti-hsp70 antibody predict risk of acute coronary syndrome Zhang, X., et al. Cell Stress Chaperones, n&list_uids= Postprocedural hyperglycemia in ST elevation myocardial infarction submitted to percutaneous coronary intervention: a prognostic indicator and a marker of metabolic derangement Lazzeri, C., et al. J Cardiovasc Med (Hagerstown), (1): p n&list_uids= Pre-hospital ECG for acute coronary syndrome in urban India: A cost-effectiveness analysis Schulman-Marcus, J., D. Prabhakaran, and T.A. Gaziano BMC Cardiovasc Disord, (1): p. 13. n&list_uids= Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial

28 Pocock, S.J., et al. Circulation, (1): p n&list_uids= Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients Roman, R.M., et al. Coron Artery Dis, n&list_uids= Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort Wakkee, M., R.M. Herings, and T. Nijsten J Invest Dermatol, (4): p n&list_uids= Relationship between serum vasoactive factors and plaque morphology in patients with non-st-segment elevated acute coronary syndrome Lu, Y.F., S.Z. Lu, and Y.D. Chen Chin Med J (Engl), (2): p n&list_uids= Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation Tang, W.H., et al. Arterioscler Thromb Vasc Biol, (3): p n&list_uids= Towards risk stratification in systemic atherosclerosis: value of myocardial function and viability imaging as an adjunct to MR angiography Seeger, A., et al. Eur Radiol, (4): p n&list_uids=

29 153. Treatment with 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients with Recent Acute Coronary Syndrome Tardif, J.C., et al. Circ Cardiovasc Imaging, n&list_uids=

1. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study Hsieh, B.P., et al. Am

More information

QUT Digital Repository:

QUT Digital Repository: QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.

More information

Appendix: ACC/AHA and ESC practice guidelines

Appendix: ACC/AHA and ESC practice guidelines Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level

More information

FastTest. You ve read the book now test yourself

FastTest. You ve read the book now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Acute Coronary syndrome

Acute Coronary syndrome Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood

More information

Heart disease is the leading cause of death

Heart disease is the leading cause of death ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population

More information

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

Otamixaban for non-st-segment elevation acute coronary syndrome

Otamixaban for non-st-segment elevation acute coronary syndrome Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Belinda Green, Cardiologist, SDHB, 2016

Belinda Green, Cardiologist, SDHB, 2016 Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens

More information

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan

More information

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:

More information

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Coronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy

Coronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case B.M. Age: 59 years Sex: female. Cardiological risk

More information

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization

More information

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan

More information

NOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS

NOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept

More information

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

An update on the management of UA / NSTEMI. Michael H. Crawford, MD An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs

More information

ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department

ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for

More information

STEMI AND MULTIVESSEL CORONARY DISEASE

STEMI AND MULTIVESSEL CORONARY DISEASE STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related

More information

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,

More information

Horizon Scanning Centre November 2012

Horizon Scanning Centre November 2012 Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG95) Chest pain of recent onset: Assessment and diagnosis

More information

La Trombosi Arteriosa

La Trombosi Arteriosa La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They

More information

Update on Antithrombotic Therapy in Acute Coronary Syndrome

Update on Antithrombotic Therapy in Acute Coronary Syndrome Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms

More information

PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS

PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS *Sudhakar George, 1 Rob Butler, 1,2 James Nolan, 1,2 Mamas A. Mamas 1,2 1. Royal Stoke University Hospital, Stoke-on-Trent, UK 2. Keele Cardiovascular

More information

Continuing Medical Education Post-Test

Continuing Medical Education Post-Test Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on

More information

Quinn Capers, IV, MD

Quinn Capers, IV, MD Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular

More information

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute

More information

European Heart Journal 2015 doi: /eurheartj/ehv320

European Heart Journal 2015 doi: /eurheartj/ehv320 European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type

More information

Novel Anticoagulation Therapy in Acute Coronary Syndrome

Novel Anticoagulation Therapy in Acute Coronary Syndrome Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux

More information

Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine

Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine Conference Papers in Medicine, Article ID 719, pages http://dx.doi.org/1.1155/13/719 Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized

More information

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to

More information

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided

More information

Timing of Surgery After Percutaneous Coronary Intervention

Timing of Surgery After Percutaneous Coronary Intervention Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet

More information

Dual Antiplatelet Therapy Made Practical

Dual Antiplatelet Therapy Made Practical Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor

More information

The Korean Society of Cardiology COI Disclosure

The Korean Society of Cardiology COI Disclosure The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific

More information

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines

More information

Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006)

Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006) Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006) 97;1182-7 n&list_uids=16616023 Value of the American College

More information

The Final 10-Year Follow-up Results from the Bari Randomized Trial J Am Coll Cardiol (2007) 49;1600-6

The Final 10-Year Follow-up Results from the Bari Randomized Trial J Am Coll Cardiol (2007) 49;1600-6 The Final 10-Year Follow-up Results from the Bari Randomized Trial J Am Coll Cardiol (2007) 49;1600-6 n&list_uids=17433949 64-Multislice Detector Computed Tomography Coronary Angiography as Potential Alternative

More information

Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine

Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:

More information

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Which drug do you prefer for stable CAD? - P2Y12 inhibitor Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A

More information

Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic

Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry) J. D. Abbott, et al. Am J Cardiol (2007) 99;626-31

More information

Acute Coronary Syndromes

Acute Coronary Syndromes Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG94) Unstable angina and NSTEMI: the early management of unstable

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Continuing Medical Education Post-Test

Continuing Medical Education Post-Test Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on

More information

Acute coronary syndromes

Acute coronary syndromes Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.

More information

Pharmacologic Therapy of Coronary Disease

Pharmacologic Therapy of Coronary Disease Pharmacologic Therapy of Coronary Disease M. MOHSEN IBRAHIM, MD Prof. of Cardiology- Cairo University President of the Egyptian Hypertension Society Introduction Coronary artery disease (CAD) is possibly

More information

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures

More information

Mario Plebani University-Hospital of Padova, Italy

Mario Plebani University-Hospital of Padova, Italy Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO

More information

Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital

Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year

More information

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%

More information

Antiplatelet therapy is the mainstay of pharmacological

Antiplatelet therapy is the mainstay of pharmacological Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science

More information

Controversies in Cardiac Pharmacology

Controversies in Cardiac Pharmacology Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?

More information

Abstract Background: Methods: Results: Conclusions:

Abstract Background: Methods: Results: Conclusions: Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li

More information

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals. OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral

More information

Unstable angina and NSTEMI

Unstable angina and NSTEMI Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the

More information

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents

More information

High-sensitive troponin. Introduction. Platelet aggregation inhibition at admission

High-sensitive troponin. Introduction. Platelet aggregation inhibition at admission Neth Heart J (2017) 25:181 185 DOI 10.1007/s12471-016-0939-y GUIDELINES 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:

More information

THE CURRENT SITUATION AND FUTURE OF THE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROM IN RUSSIAN FEDERATION

THE CURRENT SITUATION AND FUTURE OF THE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROM IN RUSSIAN FEDERATION : 616.127-005.8 -..,.. -...,, ( ), 2011, 581 182. 195 592 ( ) 385 590 -. 4,3 % 8,8 % ( ). 2011 62 329,, 24 931 (40 %) -. : - - ; ; 70 % ST ( ST); ST - 24. : ST,. THE CURRENT SITUATION AND FUTURE OF THE

More information

Guide to GRACE manuscripts (1999 to 2006)

Guide to GRACE manuscripts (1999 to 2006) Guide to GRACE manuscripts (1999 to 2006) # Topic Year of publication (enrollment period) Patient group N Summary Reference 1. Overview: study design 2001 All ACS Aim: To explain the rationale behind GRACE

More information

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

Is Cangrelor hype or hope in STEMI primary PCI?

Is Cangrelor hype or hope in STEMI primary PCI? Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect

More information

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12?

Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? La Baule Le 17 Mai 2014 Philippe Castellant CHU de Brest, Département de Cardiologie UBO,

More information

Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο

Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Europe* 2001 2011 Incident MI 291,100 327,700 US 2001 2011 Incident MI 405,100 485,200

More information

Session 7: Cardiology I and II Answer Explanations

Session 7: Cardiology I and II Answer Explanations Session 7: Cardiology I and II Answer Explanations Cardiology I 1. Answer A: Intravenous heparin 4000-unit intravenous bolus, followed by a 1000-unit/hour continuous infusion. The NSTE-ACS guidelines recommend

More information

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in

More information

bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company

bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its

More information

Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics

Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics Robert L. Jesse, MD, PhD National Program Director for Cardiology Veterans Health Administration Washington, DC Chief, Cardiology

More information

Acute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC

Acute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57

More information

Columbia University Medical Center Cardiovascular Research Foundation

Columbia University Medical Center Cardiovascular Research Foundation STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)

More information

Acute coronary syndrome (ACS) is an

Acute coronary syndrome (ACS) is an OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia

More information

Anticoagulation therapy in acute coronary syndromes according to current guidelines

Anticoagulation therapy in acute coronary syndromes according to current guidelines Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st

More information

ACUTE CORONARY SYNDROME

ACUTE CORONARY SYNDROME A supplement to MONTHLY PRESCRIBING REFERENCE April 2014 Issue #18 Intervention & Prevention: Keeping Current with ACUTE CORONARY SYNDROME JOURNAL CLUB Pretreatment with prasugrel in non-st-segment elevation

More information

Non ST Elevation-ACS. Michael W. Cammarata, MD

Non ST Elevation-ACS. Michael W. Cammarata, MD Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar

More information

Clopidogrel and ASA after CABG for NSTEMI

Clopidogrel and ASA after CABG for NSTEMI Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet

More information

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4

More information

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient

More information

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture

More information

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS

More information

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et

More information

Antithrombotic therapy in difficult clinical conditions

Antithrombotic therapy in difficult clinical conditions Antithrombotic therapy in difficult clinical conditions 4 : 5 Pankaj Manoria, PC Manoria, KK Saha, Piyush Manoria, Bhopal Introduction With the development of newer and more potent antithrombotic agents

More information

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,

More information

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1

More information

P2Y 12 blockade. To load or not to load before the cath lab?

P2Y 12 blockade. To load or not to load before the cath lab? UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,

More information